Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T29024
|
||||
| Former ID |
TTDC00325
|
||||
| Target Name |
mRNA of copper zinc superoxide dismutase 1
|
||||
| Gene Name |
SOD1
|
||||
| Synonyms |
mRNA of Superoxide dismutase 1; mRNA of Superoxide dismutase [Cu-Zn]; SOD1
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Amyotrophic lateral sclerosis [ICD9: 335.2; ICD10: G12.2] | ||||
| Motor neurone disease [ICD9: 335.2; ICD10: G12.2] | |||||
| Function |
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
|
||||
| BioChemical Class |
Oxidoreductases acting on superoxide as acceptor
|
||||
| UniProt ID | |||||
| EC Number |
EC 1.15.1.1
|
||||
| Sequence |
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ |
||||
| Structure |
1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO; 2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD; 1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO; 2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4;4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD; 1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6;2VR7; 2VR8; 2WKO; 2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD
|
||||
| Drugs and Mode of Action | |||||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| BioCyc Pathway | Reactive oxygen species degradation | ||||
| KEGG Pathway | Peroxisome | ||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington' | |||||
| s disease | |||||
| Prion diseases | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | ||||
| FOXA1 transcription factor network | |||||
| PathWhiz Pathway | Degradation of Superoxides | ||||
| Reactome | Platelet degranulation | ||||
| Detoxification of Reactive Oxygen Species | |||||
| WikiPathways | Oxidative Stress | ||||
| Copper homeostasis | |||||
| Detoxification of Reactive Oxygen Species | |||||
| Nifedipine Activity | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Dopamine metabolism | |||||
| AGE/RAGE pathway | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| Ref 522907 | ClinicalTrials.gov (NCT01041222) Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.